Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kandra Horne"'
Autor:
John N Cranmer, Shimika Barrolle, Mathu A Kumarasamy, Phyllis Wright, Kandra Horne, Nicole Franks, Courtney Omary, Helen B Mouzon, Gregory J. Esper
Publikováno v:
Journal for Healthcare Quality. 44:11-22
Patients with chronic renal failure (CRF) are at high risk of being readmitted to hospitals within 30 days. Routinely collected electronic health record (EHR) data may enable hospitals to predict CRF readmission and target interventions to increase q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::689c35f23977741dcbe4edd8193c6032
https://doi.org/10.1097/jhq.0000000000000318
https://doi.org/10.1097/jhq.0000000000000318
Autor:
Courtney, Omary, Phyllis, Wright, Mathu A, Kumarasamy, Nicole, Franks, Gregory, Esper, Helen B, Mouzon, Shimika, Barrolle, Kandra, Horne, John, Cranmer
Publikováno v:
Journal for healthcare quality : official publication of the National Association for Healthcare Quality. 44(1)
Patients with chronic renal failure (CRF) are at high risk of being readmitted to hospitals within 30 days. Routinely collected electronic health record (EHR) data may enable hospitals to predict CRF readmission and target interventions to increase q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7218af93915db65cfea869ac33d0d7e
https://pubmed.ncbi.nlm.nih.gov/34294659
https://pubmed.ncbi.nlm.nih.gov/34294659
Autor:
Chloe S. Lalonde, Christine C. Davis, Jane L. Meisel, Zhengjia Chen, Meagan Spencer Barbee, Subir Goyal, Jordyn Paige Higgins, Joan L. Kramer, Kandra Horne, Kristina F. Byers
Publikováno v:
Journal of Clinical Oncology. 38:e13085-e13085
e13085 Background: The specifics of the salvage regimen gemcitabine/carboplatin (G/C) in metastatic breast cancer (MBC) are not well-characterized and are limited to the clinical trial setting, which often excludes heavily pretreated patients with hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c69119a1d7dd3dda91a0bc1fe4446cd
https://doi.org/10.1200/jco.2020.38.15_suppl.e13085
https://doi.org/10.1200/jco.2020.38.15_suppl.e13085
Autor:
Kimberly R. Jacob Arriola, Cecil Lamonte Powell, Kari Ann Bannon, Carol Holmes, Ruth O'Regan, Tamara A. Mason, Kandra Horne
Publikováno v:
Patient Education and Counseling. 95:98-103
Objective Breast cancer incidence and mortality are declining due to improvements in early detection and treatment. One advance in treatment is the development of adjuvant endocrine therapy (AET) for women with hormone receptor positive breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f2837c471e7b5c548a4982f501b7ec8
https://doi.org/10.1016/j.pec.2013.12.019
https://doi.org/10.1016/j.pec.2013.12.019